Skip to Main Content
Table 2—

Hazard ratios of developing diabetes compared with CCB arm

ModelACE inhibitorsβ-BlockersThiazide diuretics
Primary analysis in the hypertensive cohort    
    Unadjusted 0.92 (0.81–1.0) 0.82 (0.70–0.95) — 
    Adjusted for age, sex 0.92 (0.81–1.0) 0.81 (0.70–0.95) — 
    Adjusted for age, sex, socioeconomic status, drug index, hospital index, outpatient index, and use of thiazides 0.96 (0.84–1.1) 0.85 (0.73–1.0) — 
    Adjusted for all covariates* 0.96 (0.84–1.1) 0.86 (0.74–1.0) — 
Secondary analysis: thiazide diuretics as a fourth study arm    
    Adjusted analysis* 0.97 (0.83–1.1) 0.84 (0.7–1.0) 1.0 (0.89–1.2) 
ModelACE inhibitorsβ-BlockersThiazide diuretics
Primary analysis in the hypertensive cohort    
    Unadjusted 0.92 (0.81–1.0) 0.82 (0.70–0.95) — 
    Adjusted for age, sex 0.92 (0.81–1.0) 0.81 (0.70–0.95) — 
    Adjusted for age, sex, socioeconomic status, drug index, hospital index, outpatient index, and use of thiazides 0.96 (0.84–1.1) 0.85 (0.73–1.0) — 
    Adjusted for all covariates* 0.96 (0.84–1.1) 0.86 (0.74–1.0) — 
Secondary analysis: thiazide diuretics as a fourth study arm    
    Adjusted analysis* 0.97 (0.83–1.1) 0.84 (0.7–1.0) 1.0 (0.89–1.2) 

Data are hazard ratios (95% CI).

*

Adjusted for age, sex, socioeconomic status, hospitalization index, outpatient index, drug index, rural residence, and use of niacin, phenytoin, resins, statins, α-blockers, atypical antipsychotics, corticosteroids, fibrates, and lithium. The primary analysis is also adjusted for thiazide diuretic use.

Close Modal

or Create an Account

Close Modal
Close Modal